The addition of inotuzumab ozogamicin to hyper-CVAD + blinatumomab in patients with B-ALL

The safety and efficacy of hyper-CVAD plus blinatumomab and inotuzumab ozogamicin in Ph- ALLПодробнее

Hyper-CVAD with blinatumomab and inotuzumab ozogamicin for patients with newly diagnosed Ph- B-ALLПодробнее

Choosing between inotuzumab ozogamicin and blinatumomab in patients with R/R ALLПодробнее

Hyper-CVAD and sequential blinatumomab in adults with newly diagnosed Philadelphia chromosome-ne...Подробнее

Alliance A041501: the addition of inotuzumab to a pediatric-inspired chemo regimen for B-ALLПодробнее

Blinatumomab vs inotuzumab ozogamicin for ALLПодробнее

Updated results of hyper-CVAD and blinatumomab +/- inotuzumab ozogamicin in newly-diagnosed B-ALLПодробнее

Outcomes of patients with newly diagnosed CRLF2-rearranged B-ALLПодробнее

Addition of blinatumomab to mini-hyper-CVD and inotuzumab improves outcomes in R/R ALLПодробнее

Blinatumomab and inotuzumab in children with R/R B-ALLПодробнее

Blinatumomab therapy following hyper-CVAD in B-cell ALLПодробнее

Inotuzumab ozogamicin and blinatumomab prior to and after alloHSCT in R/R Ph+ ALLПодробнее

Mini-hyper-CVD + InO followed by blina consolidation for R/R ALLПодробнее

Safety and efficacy of blinatumomab and inotuzumab ozogamicin in multiple relapsed ALLПодробнее

The importance of blinatumomab and inotuzumab ozogamicin in treating ALLПодробнее

Novel targeted antibodies for R/R B-ALLПодробнее

Inotuzumab ozogamicin and chemotherapy with or without blinatumomab in Philadelphia chromosone-n...Подробнее

Real-world outcomes of patients with R/R B-ALL treated with blinatumomab and inotuzumab ozogamicinПодробнее

Phase II study of inotuzumab ozogamicin in MRD+ B-ALLПодробнее